Angel Soto‐Hermida

751 citations
17 papers · 539 indexed · h-index 13

Angel Soto‐Hermida

17 papers receiving 533 citations

Peers

Angel Soto‐Hermida
Comparison fields: 5 of 70
  • Rheumatology 292
  • Cancer Research 120
  • Pharmacology 76
  • Molecular Biology 302
  • Ophthalmology 34
Replace M.H. van den Bosch with:
M.H. van den Bosch Netherlands
Ye He China
Donglai Wang China
Ahmet Arman Türkiye
Burçak Vural Türkiye
Yasuo Kuroki Japan
Shin-Long Wu Taiwan
Sofia Töyrä Silfverswärd Sweden
Leizhou Xia China
Tashjian Ah United States
Angel Soto‐Hermida relative to M.H. van den Bosch Netherlands M.H. van den Bosch's profile →
Citations per field
00.5×10×17×
M.H. van den Bosch · 1×
Citations per year

Countries citing papers authored by Angel Soto‐Hermida

Since Specialization
Citations

This map shows the geographic impact of Angel Soto‐Hermida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angel Soto‐Hermida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angel Soto‐Hermida more than expected).

Fields of papers citing papers by Angel Soto‐Hermida

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angel Soto‐Hermida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angel Soto‐Hermida. The network helps show where Angel Soto‐Hermida may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Angel Soto‐Hermida, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Angel Soto‐Hermida Line = papers co-authored together Angel Soto‐Hermida links everyone, so they are left out of the graph.

All Works

17 of 17 papers shown
#Work
1 20252
2 202056
3 201923
4 201811
5 201811
6 201713
7 201628
8 201666
9 201433
10 201422
11 201422
12 20132
13 2013129
14 201223
15 201135
16 201131
17 201032

About Angel Soto‐Hermida

Angel Soto‐Hermida is a scholar working on Rheumatology, Ophthalmology and Molecular Biology, having authored 17 papers that have together received 539 indexed citations. Recurring topics across this work include Osteoarthritis Treatment and Mechanisms (9 papers), Retinal Development and Disorders (3 papers), Peroxisome Proliferator-Activated Receptors (3 papers), Rheumatoid Arthritis Research and Therapies (3 papers), Mitochondrial Function and Pathology (2 papers), Retinal Diseases and Treatments (2 papers), Inflammatory mediators and NSAID effects (2 papers) and Pulmonary Hypertension Research and Treatments (2 papers). The work is most often cited by research in Rheumatology (292 citations), Cancer Research (120 citations) and Pharmacology (76 citations). Angel Soto‐Hermida has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Ignacio Rego‐Pérez, Francisco J. Blanco, M. Fernández-Moreno, C. Fernández-López, N. Oreiro, Sónia Pértega-Díaz, M.E. Vázquez-Mosquera, José Luís Fernández, Alejandro Mosquera and Juan Fernández‐Tajes. Their work appears in journals such as PLoS ONE, Science Translational Medicine and Annals of the Rheumatic Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026